Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Share-based Compensation (2023 - 2025)

CG Oncology's Share-based Compensation history spans 3 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 44.03% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $26.7 million, up 133.96%, while the annual FY2025 figure was $26.7 million, 133.96% up from the prior year.
  • Share-based Compensation reached $7.2 million in Q4 2025 per CGON's latest filing, down from $7.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q3 2025 to a low of $177000.0 in Q2 2023.
  • Average Share-based Compensation over 3 years is $3.3 million, with a median of $2.4 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: soared 1168.93% in 2024, then skyrocketed 44.03% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $778000.0 in 2023, then skyrocketed by 541.39% to $5.0 million in 2024, then surged by 44.03% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Share-based Compensation are $7.2 million (Q4 2025), $7.3 million (Q3 2025), and $7.0 million (Q2 2025).